{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:34:57Z","timestamp":1793745297850,"version":"4.6.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Early phase clinical trials evaluate the safety and efficacy of new treatments. The exclusion\/inclusion criteria in these trials are usually rigorous and may exclude many patients seen in clinical practice. Our objective was to study the comorbidities limiting the participation of patients with breast, colorectal, or lung cancer in clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We queried ClinicalTrials.gov on December 31, 2016. We reviewed the eligibility criteria of 1,103 trials. Logistic regression analyses were completed, and exclusion was studied as a binary variable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of 1,103 trials, 70 trials (6%) excluded patients &amp;gt;75 years of age, and 45% made no reference to age. Eighty-six percent of trials placed restrictions on patients with history of prior malignancies. Regarding central nervous system (CNS) metastasis, 416 trials (38%) excluded all patients with CNS metastasis, and 373 (34%) only allowed asymptomatic CNS metastasis. Regarding chronic viral infections, 347 trials (31%) excluded all patients with human immunodeficiency virus, and 228 trials (21%) excluded all patients with hepatitis B or C infection. On univariate analysis, chemotherapy trials were more likely to exclude patients with CNS metastasis and history of other malignancies than targeted therapy trials. Multivariate analysis demonstrated that industry-sponsored trials had higher odds of excluding patients with compromised liver function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Many clinical trials excluded large segments of the population of patients with cancer. Frequent exclusion criteria included patients with CNS metastasis, history of prior malignancies, and chronic viral infections. The criteria for participation in some clinical trials may be overly restrictive and limit enrollment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>The results of this study revealed that most early phase clinic trials contain strict exclusion criteria, potentially excluding the patients who may be more likely to represent the population treated in clinical settings, leaving patients susceptible to unintended harm from inappropriate generalization of trial results. Careful liberalization of the inclusion\/exclusion criteria in clinical trials will allow investigators to understand the benefits and drawbacks of the experimental drug for a broader population, and possibly improve recruitment of patients with cancer into clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0687","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T15:45:55Z","timestamp":1541778355000},"page":"96-102","source":"Crossref","is-referenced-by-count":53,"title":["Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials"],"prefix":"10.1093","volume":"24","author":[{"given":"Narjust","family":"Duma","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal M.","family":"Kothadia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq U.","family":"Azam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Vera Aguilera","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gonzalez Velez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur Ragnar","family":"Halfdanarson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R.","family":"Molina","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen M.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"2021122506214017500_onco12736-bib-0001","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.5888\/pcd13.160211","article-title":"Heart disease and cancer deaths - Trends and projections in the United States, 1969-2020","volume":"13","author":"Weir","year":"2016","journal-title":"Prev Chronic Dis"},{"key":"2021122506214017500_onco12736-bib-0002","first-page":"147","article-title":"Cancer in the elderly","volume":"117","author":"Berger","year":"2006","journal-title":"Trans Am Clin Climat Assoc"},{"key":"2021122506214017500_onco12736-bib-0003","author":"Trends, charts, and maps","year":"2017"},{"issue":"suppl 1","key":"2021122506214017500_onco12736-bib-0004","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2105\/AJPH.2009.162982","article-title":"Disparate inclusion of older adults in clinical trials: Priorities and opportunities for policy and practice change","volume":"100","author":"Herrera","year":"2010","journal-title":"Am J Public Health"},{"key":"2021122506214017500_onco12736-bib-0005","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1200\/JOP.2014.001388","article-title":"Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (Alliance)","volume":"10","author":"Klepin","year":"2014","journal-title":"J Oncol Pract"},{"key":"2021122506214017500_onco12736-bib-0006","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/JTO.0b013e3181fbebfd","article-title":"Comparison of platinum-based chemotherapy in patients older and younger than 70 years of age: An analysis of Southwest Oncology Group trials 9308 and 9509","volume":"6","author":"Blanchard","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2021122506214017500_onco12736-bib-0007","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","article-title":"Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials","volume":"23","author":"Townsley","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0008","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2407-6-34","article-title":"Understanding the attitudes of the elderly towards enrolment into cancer clinical trials","volume":"6","author":"Townsley","year":"2006","journal-title":"BMC Cancer"},{"key":"2021122506214017500_onco12736-bib-0009","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0010","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"KEYNOTE Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122506214017500_onco12736-bib-0011","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1158\/1078-0432.CCR-16-0338","article-title":"Challenges facing early phase trials sponsored by the National Cancer Institute: An analysis of corrective action plans to improve accrual","volume":"22","author":"Massett","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122506214017500_onco12736-bib-0012","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2007.1.489","article-title":"Are there circumstances in which phase 2 study results should be practice-changing?","author":"Tomblyn","year":"2007","journal-title":"Hematology am Soc Hematol Educ Program"},{"key":"2021122506214017500_onco12736-bib-0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2021122506214017500_onco12736-bib-0014","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"key":"2021122506214017500_onco12736-bib-0015","volume-title":"Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities. Workshop Summary","author":"Institute of Medicine Forum on Drug Discovery","year":"2010"},{"key":"2021122506214017500_onco12736-bib-0016","first-page":"269","article-title":"How have cancer clinical trial eligibility criteria evolved over time?","volume":"2016","author":"Yaman","year":"2016","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"key":"2021122506214017500_onco12736-bib-0017","first-page":"1487","article-title":"Drug dosing adjustments in patients with chronic kidney disease","volume":"75","author":"Munar","year":"2007","journal-title":"American Fam Physician"},{"key":"2021122506214017500_onco12736-bib-0018","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0019","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jtho.2015.10.024","article-title":"A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: A review of the ClinicalTrials.gov trial registry","volume":"11","author":"McCoach","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"suppl 15","key":"2021122506214017500_onco12736-bib-0020","doi-asserted-by":"crossref","first-page":"9009A","DOI":"10.1200\/jco.2015.33.15_suppl.9009","article-title":"Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases","volume":"33","author":"Kluger","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0021","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: Proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncology"},{"key":"2021122506214017500_onco12736-bib-0022","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0023","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122506214017500_onco12736-bib-0024","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bmj.a3172","article-title":"Clinical review: HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity","volume":"338","author":"Deeks","year":"2009","journal-title":"BMJ"},{"key":"2021122506214017500_onco12736-bib-0025","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0026","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2015.62.1854","article-title":"Modernizing eligibility criteria for molecularly driven trials","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0027","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2001.19.6.1728","article-title":"Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment","volume":"19","author":"Lara","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0028","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1634\/theoncologist.2014-0093","article-title":"Exclusion of older patients from ongoing clinical trials for hematological malignancies: An evaluation of the national institutes of health clinical trial registry","volume":"19","author":"Hamaker","year":"2014","journal-title":"The Oncologist"},{"key":"2021122506214017500_onco12736-bib-0029","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1200\/EDBK_179803","article-title":"Strategies to maximize patient participation in clinical trials","volume":"37","author":"Rubin","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2021122506214017500_onco12736-bib-0030","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: Analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122506214017500_onco12736-bib-0031","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jtho.2017.07.020","article-title":"Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity","volume":"12","author":"Garcia","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2021122506214017500_onco12736-bib-0032","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2011.40.1125","article-title":"The American Society of Clinical Oncology's blueprint for transforming clinical and translational cancer research","volume":"30","author":"Meropol","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0687","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0687","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/1\/96\/41917087\/oncolo_24_1_96.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/1\/96\/41917087\/oncolo_24_1_96.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:22:19Z","timestamp":1640413339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/1\/96\/6439024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,11,9]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0687","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1,1]]},"published":{"date-parts":[[2018,11,9]]}}}